FDA Greenlights Trial for Duchenne Gene-Editing Therapy
The U.S. Food and Drug Administration has approved a clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne Muscular Dystrophy (DMD). The first-in-human study, named FUNCTION-DMD, represents a significant regulatory step for advanced therapies targeting complex genetic conditions. A virtual event to provide further details on the study is scheduled for March.
- Duchenne Muscular Dystrophy (DMD) is a genetic disorder stemming from mutations in the gene that produces dystrophin, a protein crucial for muscle fiber integrity. The disease, which affects approximately 1 in every 3,500 to 5,000 male births worldwide, leads to progressive muscle degeneration, impacting skeletal, heart, and lung muscles. - The therapy, PBGENE-DMD, uses a gene-editing technology called ARCUS to make a single, permanent edit to a patient's DNA. This one-time treatment is designed to excise a mutated portion of the dystrophin gene, specifically targeting mutations that fall between exons 45 and 55. This region is considered a mutational "hot-spot" and is estimated to be the cause of DMD in approximately 60% of patients. - Unlike some other therapeutic approaches, this gene-editing technique aims to restore the body's ability to naturally produce a near full-length, functional dystrophin protein. Preclinical studies in mouse models have shown this method can restore dystrophin production in skeletal and cardiac muscles and even in muscle stem cells, suggesting the potential for long-term benefits. - The ARCUS platform, proprietary to Precision BioSciences, is distinct from CRISPR-based systems and is being developed for other genetic and infectious diseases, such as chronic Hepatitis B. The therapy is delivered using a single adeno-associated virus (AAV) vector, a common method for in vivo gene therapy. - The global Duchenne treatment market was valued at $3.2 billion in 2023 and is projected to reach $8.6 billion by 2032, indicating a significant market opportunity for new entrants with effective therapies. Other gene-based treatments are also in development or recently approved, such as Sarepta Therapeutics' Elevidys, which uses a micro-dystrophin approach and received expanded FDA approval in mid-2024. - In Turkey, the deeptech sector, including biotechnology, represents a small but growing fraction of the startup ecosystem, with only 14.3% of deeptech startups having secured investment. While venture capital investment is increasing, it has predominantly favored software-based ventures over capital-intensive fields like biotech. - Health and biotechnology was one of the leading sectors in Turkey for the number of investment deals in the first nine months of 2025, although it lagged significantly behind fintech and gaming in total capital raised. Turkish VCs like Diffusion Capital Partners are specifically focused on deeptech opportunities, including biotech and life sciences, signaling growing investor interest in the space.
